Pendal Group LTD Biomarin Pharmaceutical Inc Transaction History

Pendal Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	BUY	$71.48 - $86.85 $401,360 - $487,662	5,615 New	5,615 $465,000
Q4 2019 Feb 06, 2020	SELL	$64.27 - $86.37 $734,541 - $987,122	-11,429 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $62,075 - $78,386	-921 Reduced 7.46%	11,429 $770,000
Q2 2019 Aug 01, 2019	BUY	$80.35 - $93.9 $49,977 - $58,405	622 Added 5.3%	12,350 $0
Q4 2018 Jan 30, 2019	SELL	$80.14 - $106.07 $400 - $530	-5 Reduced 0.04%	11,728 $998,000
Q2 2018 Jul 18, 2018	SELL	$76.01 - $99.03 $988 - $1,287	-13 Reduced 0.11%	11,733 $0
Q1 2018 May 08, 2018	BUY	$77.67 - $92.63 $12,504 - $14,913	161 Added 1.39%	11,746 $0
Q4 2017 Feb 06, 2018	BUY	$80.76 - $95.13 $41,349 - $48,706	512 Added 4.62%	11,585 $0
Q3 2017 Nov 01, 2017	BUY	$80.6 - $94.95 $359,717 - $423,761	4,463 Added 67.52%	11,073 $0
Q2 2017 Aug 11, 2017	BUY	N/A	6,610	6,610 $0

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Pendal Group LTD, based on Form 13F filings with the SEC.

Stay updated on Pendal Group LTD with notifications on news.